Search

everythinglearnresearchcommunity

for

Search:↓

A user mixed a pyrilutamide solution and noticed undissolved powder at the bottom, questioning if this is normal and how long to wait before applying it. They wished others good luck with their treatments.

Orient Bio is developing a PLGA formulated version of Cyclosporine A to stimulate hair growth without its immunosuppressant effects. Users discuss various treatments like Clascoterone, PP405, minoxidil, and tacrolimus, expressing hope for new developments and sharing personal experiences with these treatments.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

The conversation discusses the effectiveness of pyrithione zinc and GT20029 for hair loss. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The user is considering switching from pyrilutamide to 0.025% topical finasteride due to concerns about effectiveness and past side effects from a scalp elixir. They aim to maintain hair until new treatments like breezula or GT00029 become available.

Cyproterone Acetate stopped hair loss and led to regrowth on the temples for a transgender individual, which is considered a good sign. Unlike Minoxidil and Finasteride, which can cause initial shedding, Cyproterone did not cause shedding.

User discusses using C60 serum with microneedling at 1.75mm and asks if it's safe. Current routine includes daily Pyril on temples, weekly microneedling, and C60 serum on non-Pyril days.

A user who is using Pyrilutamide, Finasteride, and a homemade topical solution to treat their hair loss. Replies mentioned the potential of Pyrilutamide being a "cure" for hair loss and a reminder that results may not be credited solely to it.

Dr. Tsuji is giving online lectures about hair multiplication trials. Users express hope for a cure, but some are skeptical about its timeline.

The conversation discusses Pyrilutamide for hair loss, with skepticism about its legitimacy and mentions of an upcoming press release from Kintor. It also references ongoing trials and includes links for further information.

Hair loss discussion involves pyrilutamide treatment. Slow regrowth observed, expecting 10 baby hairs on temple regions after 1 year.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

Minoxidil, finasteride, dutasteride, and microneedling are commonly used for temple regrowth, with varying results and timelines. Consistency and patience are emphasized, with some users seeing progress after several years.

The conversation is about a new acne treatment cream called Clascoterone Cream 1%, which is the first new mechanism of action for acne in nearly 40 years. One person joked about hoping their face will be as clean as their bald head after using the cream.

The user is using dutasteride, oral minoxidil, and topical minoxidil with tretinoin for hair loss. They are considering whether to continue this treatment or opt for a hair transplant for their temples.

The conversation discusses personal experiences with hair loss treatments, specifically Minoxidil and Finasteride, with some users regretting not starting treatment earlier and others experiencing side effects. Some users are considering or have switched to topical formulations due to side effects from oral medications.

The conversation is about someone experiencing continued hair loss despite using Pyrilutamide and considering the need for more time or better quality control for the treatment. Another person suggests waiting for the drug to be officially approved due to potential quality issues with current products.

An update on the use of Pyrilutamide, a new drug for hair loss, which has resulted in no shedding or testicle ache; other users have questioned the science behind this and shared their own experiences with Finasteride, Minoxidil, and microneedling.

The discussion is about a hair loss drug called pyrilutamide. Users discuss its efficacy, safety, and expected market release around 2025-2026, with some expressing concerns about the authenticity of current market offerings.

A user is excited to start using Pyriltamide for hair loss after experiencing side effects from topical finasteride. Other users discuss the potential and skepticism of Pyriltamide compared to older treatments like finasteride and RU58841.

The user is using a routine involving microneedling, Minoxidil with tretinoin, a red light cap, scalp massages, Nizoral shampoo, and essence oil shampoo to address hair loss, with visible progress noted. They are considering topical finasteride or dutasteride if progress slows but are cautious due to past side effects.

The conversation discusses hair loss treatments, specifically using Minoxidil, finasteride, and RU58841. The focus is on progress observed at the temples after one month of treatment.

The user reports temple hair regrowth using RU58841, minoxidil, and finasteride, recently switching to dutasteride. They consider stopping RU58841 and continuing with oral minoxidil and dutasteride.

Tae147 has shared results of using pyrilutamide, a 5% concentration topical solution applied twice daily, in combination with minoxidil, to reduce scalp itchiness and hair shedding. Other users have shared their experiences with the treatment, as well as questions about its availability on the market.

Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.

The conversation is about whether the phase 2 results for pyrilutamide, a potential hair loss treatment, were presented at a dermatology convention and inquiries about the completion of phase 3 trials. Specific treatments mentioned include pyrilutamide.

Kintor is launching pyrilutamide as a cosmetic for hair loss. Users discuss its potential, comparing it to Cosmerna.

Using a combination of low-dose topical finasteride (0.025%) and 0.5% pyrilutamide for hair loss, with a focus on minimizing side effects. The user seeks experiences and results from others who have tried this combination.